Trang 1 từ 25 các kết quả
1. STUDY SYNOPSIS 1.1 Rationale Psoriatic arthritis (PsA) is a chronic inflammatory disease, leading to impaired function, reduced quality of life, comorbidities and increased mortality. Fortunately, improved knowledge about disease mechanisms catalyzed rapid development of effective targeted
The study will be conducted in compliance with International Standard good clinical practices (GCPs) and the Declaration of Helsinki. The protocol was approved by local Institutional Review Board and registered in clinical trials.gov.
Clinical and Laboratory Evaluation Blood counts and liver
Over one million infants are born to HIV-1-infected women every year in Sub Saharan Africa. In Zimbabwe, annual births stand at 379,000 with approximately 48,000 infants being born every year to HIV-1-infected women on lifelong highly active antiretroviral therapy (HAART). Concerns have been
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Based on previous and ongoing clinical trials demonstrating
Antiretroviral therapy has changed the natural history of HIV infection. However, antiretroviral therapy must be maintained for life. Its potential long-term adverse effects may interact synergistically with the ageing process, resulting in a higher incidence of comorbidities. The increasing number
The results of the screening of volunteers who signed the informed consent Form, is a sequence set in three groups of volunteers with different doses of the drug, the total number of volunteers who received the drug will be at least 25 people.
Taking into account the fact that for the first time the
Hemodialysis (HD) is the most worldwide prescribed renal replacement therapy for patients with end-stage renal disease. This treatment that relies heavily on technology has undergone major modifications in the last five decades in order to improve patients' outcomes. Those changes that aimed at
Study disease:
In 2014 it was estimated that 36.9 million people worldwide were living with HIV and since the beginning of the epidemic, about 36 million have died of HIV.
There are many research strategies underway to try to reduce the devastating effects of this disease and to prevent onward
Each subject must sign and date a study-specific informed consent form (ICF) prior to their participation in any screening activities. Prospective subjects should be screened no more than 28 days prior to administration of the first dose of study drug on Day 1. Screening evaluations will be used to
Objectives The primary endpoint will be the description of the proportion of participants with an HIV-1 viral load < 50 copies/mL.
The secondary endpoints will be:
- Change from Baseline in CD4+ T-cell counts, CD8 cell counts, CD4/ CD8 ratio
- Proportion of subjects with laboratory alterations
-
Adult, male and female HIV-1 infected subjects, who started an antiretroviral regimen of RALTEGRAVIR plus ABACAVIR and LAMIVUDINE after a different antiretroviral regimen.
Subject Selection: Inclusion Criteria
All consecutive patients fulfilling the following inclusion criteria will be considered:
-
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. We propose to treat 21 adult patients with chronic delta hepatitis
The population to be studied will consist of neonates born to mothers presenting with clinical symptoms of Chikungunya within six days before and two days after childbirth. These neonates will therefore be exposed to a high risk of developing a severe form of Chikungunya infection. In most cases the
This is a safety/efficacy phase II, open, randomized, controlled clinical trial, with two arms. The study population will consist of 30 patients with chronic decompensated liver disease (Child-Pugh B or C). The candidates included in the study will be asked to voluntarily participate and sign the
1. HYPOTHESIS AND OBJECTIVES PEG-IFN as an immunomodulatory agent could potentiate the antiviral efficacy of patients on long term nucleos(t)ide analogue therapy and improve early indicators of efficacy, HBeAg loss and reduction in qHBsAg. This study will also test whether add-on compared to switch